Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tcr2 Therapeutics Inc (NQ: TCRR ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Tcr2 Therapeutics Inc < Previous 1 2 3 4 Next > Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying May 11, 2023 The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... Via Benzinga Recap: TCR2 Therapeutics Q1 Earnings May 11, 2023 Via Benzinga TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 11, 2023 From TCR2 Therapeutics Via GlobeNewswire TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 08, 2023 From TCR2 Therapeutics Via GlobeNewswire What To Know About Jefferies's Downgrade of TCR2 Therapeutics March 09, 2023 Via Benzinga 4 Analysts Have This to Say About TCR2 Therapeutics March 09, 2023 Via Benzinga Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company March 06, 2023 Via Benzinga Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying May 08, 2023 The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... Via Benzinga TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR April 26, 2023 From Kahn Swick & Foti, LLC Via Business Wire TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 03, 2023 From TCR2 Therapeutics Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC – March 30, 2023 From Brodsky & Smith LLC Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 March 24, 2023 Via Benzinga TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update March 23, 2023 From TCR2 Therapeutics Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 March 09, 2023 Via Benzinga TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR March 08, 2023 From Kahn Swick & Foti, LLC Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023 March 08, 2023 Via Benzinga Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason March 07, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 March 07, 2023 Via Benzinga Why Is TCR2 Therapeutics Stock Trading Higher Today? March 06, 2023 TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to... Via Benzinga Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 06, 2023 Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session March 06, 2023 Via Benzinga TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company March 06, 2023 TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of Via Spotlight Growth Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? March 06, 2023 A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors. Via InvestorPlace TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders March 06, 2023 From Halper Sadeh LLC Via Business Wire 12 Health Care Stocks Moving In Monday's Pre-Market Session March 06, 2023 Via Benzinga Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors March 06, 2023 Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors... Via Newsfile Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors March 06, 2023 From TCR2 Therapeutics Via GlobeNewswire TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023 February 08, 2023 From TCR2 Therapeutics Via GlobeNewswire CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC January 06, 2023 Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest. Via InvestorPlace Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 06, 2023 Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.